Chapter 5: Epigenomic Sequencing Technologies
-
Published:30 Sep 2024
-
Special Collection: 2024 eBook CollectionSeries: Drug Discovery
J. Chen, T. Keshavarzian, and M. Lupien, in Epigenetic Drug Discovery, ed. H. M. Chan and C. Arrowsmith, Royal Society of Chemistry, 2024, vol. 83, ch. 5, pp. 109-157.
Download citation file:
The epigenome harbors diverse sets of DNA elements that can be revealed with distinct sequencing technologies. Epigenomic sequencing studies identify chromatin states to partition the genome into DNA elements and find alterations between healthy and disease settings, known as chromatin variants, to identify the genetic basis of disease. These disease-associated chromatin variants serve as biomarkers and define vulnerabilities for epigenetic therapy. Epigenomic sequencing technologies are constantly evolving and their adoption for clinical uptake should be considered to improve therapeutic applicability.